It has been estimated that there may be thousands of target genes for miR-155, although significant overlap has been observed between miR-155 targets and the molecular profile of mutant p53-expressing breast tumours suggesting that this may prove to be a particularly useful target with fewer side-effects [52]. This evidence concerns the gene TP53 and breast neoplasm.